Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.

Bove R, Rankin K, Lin C, Zhao C, Correale J, Hellwig K, Michel L, Laplaud DA, Chitnis T.

Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118. [Epub ahead of print]

PMID:
31368394
2.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

PMID:
31300547
3.

Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.

Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R.

Mult Scler. 2019 May 31:1352458519849511. doi: 10.1177/1352458519849511. [Epub ahead of print]

PMID:
31148523
4.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
5.

Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons.

Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, Crabé R, Virenque A, Soulard C, Fierle JK, Brodovitch A, Libralato M, Végh AG, Venteo S, Scamps F, Boucraut J, Laplaud D, Hernandez J, Gergely C, Vincent T, Raoul C.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2312-2317. doi: 10.1073/pnas.1815961116. Epub 2019 Jan 23.

6.

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M; the OFSEP Investigators.

Mult Scler. 2018 Dec 13:1352458518815602. doi: 10.1177/1352458518815602. [Epub ahead of print]

PMID:
30541380
7.

Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines.

Perriot S, Mathias A, Perriard G, Canales M, Jonkmans N, Merienne N, Meunier C, El Kassar L, Perrier AL, Laplaud DA, Schluep M, Déglon N, Du Pasquier R.

Stem Cell Reports. 2018 Nov 13;11(5):1199-1210. doi: 10.1016/j.stemcr.2018.09.015. Epub 2018 Oct 25.

8.

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S; Société Francophone de la Sclérose en Plaques.

J Neurol. 2018 Oct;265(10):2251-2259. doi: 10.1007/s00415-018-8984-7. Epub 2018 Jul 27.

PMID:
30054790
9.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

10.

Microglial control of astrocytes in response to microbial metabolites.

Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao CC, Ardura-Fabregat A, de Lima KA, Gutiérrez-Vázquez C, Hewson P, Staszewski O, Blain M, Healy L, Neziraj T, Borio M, Wheeler M, Dragin LL, Laplaud DA, Antel J, Alvarez JI, Prinz M, Quintana FJ.

Nature. 2018 May;557(7707):724-728. doi: 10.1038/s41586-018-0119-x. Epub 2018 May 16.

11.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
12.

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP.

Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Review.

PMID:
29606320
13.

Immuno-Guided Laser-Capture Microdissection of Glial Cells for mRNA Analysis.

Nicot AB, Rambeau J, Guillot F, Garcia A, Laplaud DA.

Methods Mol Biol. 2018;1723:261-271. doi: 10.1007/978-1-4939-7558-7_15.

PMID:
29344866
14.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
15.

Is the Choosing Wisely® campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study.

Trumbic B, Zéphir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, de Sèze J.

Rev Neurol (Paris). 2018 Jan - Feb;174(1-2):28-35. doi: 10.1016/j.neurol.2017.06.016. Epub 2017 Nov 8.

PMID:
29128151
16.

An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8+ T cells involved in multiple sclerosis.

Nicol B, Salou M, Vogel I, Garcia A, Dugast E, Morille J, Kilens S, Charpentier E, Donnart A, Nedellec S, Jacq-Foucher M, Le Frère F, Wiertlewski S, Bourreille A, Brouard S, Michel L, David L, Gourraud PA, Degauque N, Nicot AB, Berthelot L, Laplaud DA.

J Autoimmun. 2018 Mar;88:61-74. doi: 10.1016/j.jaut.2017.10.005. Epub 2017 Oct 18.

17.

IL-15 Harnesses Pro-inflammatory Function of TEMRA CD8 in Kidney-Transplant Recipients.

Tilly G, Doan-Ngoc TM, Yap M, Caristan A, Jacquemont L, Danger R, Cadoux M, Bruneau S, Giral M, Guerif P, Nicol B, Garcia A, Laplaud DA, Brouard S, Pecqueur Hellman C, Degauque N.

Front Immunol. 2017 Jun 30;8:778. doi: 10.3389/fimmu.2017.00778. eCollection 2017.

18.

Decrease of blood anti-α1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients.

Le Berre L, Rousse J, Gourraud PA, Imbert-Marcille BM, Salama A, Evanno G, Semana G, Nicot A, Dugast E, Guérif P, Adjaoud C, Freour T, Brouard S, Agbalika F, Marignier R, Brassat D, Laplaud DA, Drouet E, Van Pesch V, Soulillou JP.

Clin Immunol. 2017 Jul;180:128-135. doi: 10.1016/j.clim.2017.05.006. Epub 2017 May 18.

19.

Cost-effectiveness of home telemonitoring in chronic kidney disease patients at different stages by a pragmatic randomized controlled trial (eNephro): rationale and study design.

Thilly N, Chanliau J, Frimat L, Combe C, Merville P, Chauveau P, Bataille P, Azar R, Laplaud D, Noël C, Kessler M.

BMC Nephrol. 2017 Apr 5;18(1):126. doi: 10.1186/s12882-017-0529-2.

20.

Can we discontinue disease-modifying treatments in multiple sclerosis patients? Yes.

Laplaud D.

Rev Neurol (Paris). 2017 Jan - Feb;173(1-2):38-40. doi: 10.1016/j.neurol.2016.10.005. Epub 2016 Dec 10. No abstract available.

PMID:
27955826
21.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
22.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
23.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Lanzillo R, Moccia M, Laplaud DA, Foucher Y.

Neurology. 2016 Sep 6;87(10):1066. doi: 10.1212/01.wnl.0000497026.62085.8d. No abstract available.

PMID:
27597557
24.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Bhatia R, Laplaud DA, Foucher Y.

Neurology. 2016 Sep 6;87(10):1065-6. doi: 10.1212/WNL.0000000000003112. No abstract available. Erratum in: Neurology. 2016 Nov 1;87(18):1961.

PMID:
27597556
25.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

26.

Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis.

Salou M, Nicol B, Garcia A, Baron D, Michel L, Elong-Ngono A, Hulin P, Nedellec S, Jacq-Foucher M, Le Frère F, Jousset N, Bourreille A, Wiertlewski S, Soulillou JP, Brouard S, Nicot AB, Degauque N, Laplaud DA.

Clin Immunol. 2016 May;166-167:1-11. doi: 10.1016/j.clim.2016.03.014. Epub 2016 Apr 2.

PMID:
27050759
27.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

28.

Involvement of CD8(+) T Cells in Multiple Sclerosis.

Salou M, Nicol B, Garcia A, Laplaud DA.

Front Immunol. 2015 Nov 26;6:604. doi: 10.3389/fimmu.2015.00604. eCollection 2015. Review.

29.

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.

Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P.

Mult Scler. 2016 Jun;22(7):944-54. doi: 10.1177/1352458515606809. Epub 2015 Oct 7.

PMID:
26447066
30.

Transcript analysis of laser capture microdissected white matter astrocytes and higher phenol sulfotransferase 1A1 expression during autoimmune neuroinflammation.

Guillot F, Garcia A, Salou M, Brouard S, Laplaud DA, Nicot AB.

J Neuroinflammation. 2015 Jul 4;12:130. doi: 10.1186/s12974-015-0348-y.

31.

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G; COPOUSEP investigators; West Network for Excellence in Neuroscience.

Lancet. 2015 Sep 5;386(9997):974-81. doi: 10.1016/S0140-6736(15)61137-0. Epub 2015 Jun 28. Erratum in: Lancet. 2016 Jan 23;387(10016):340.

32.

Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis.

Salou M, Garcia A, Michel L, Gainche-Salmon A, Loussouarn D, Nicol B, Guillot F, Hulin P, Nedellec S, Baron D, Ramstein G, Soulillou JP, Brouard S, Nicot AB, Degauque N, Laplaud DA.

Ann Clin Transl Neurol. 2015 Jun;2(6):609-22. doi: 10.1002/acn3.199. Epub 2015 Apr 28.

33.

Decreased Frequency of Circulating Myelin Oligodendrocyte Glycoprotein B Lymphocytes in Patients with Relapsing-Remitting Multiple Sclerosis.

Elong Ngono A, Lepetit M, Reindl M, Garcia A, Guillot F, Genty A, Chesneau M, Salou M, Michel L, Lefrere F, Schanda K, Imbert-Marcille BM, Degauque N, Nicot A, Brouard S, Laplaud DA, Soulillou JP.

J Immunol Res. 2015;2015:673503. doi: 10.1155/2015/673503. Epub 2015 May 18.

34.

αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell-related features.

Held K, Bhonsle-Deeng L, Siewert K, Sato W, Beltrán E, Schmidt S, Rühl G, Ng JK, Engerer P, Moser M, Klinkert WE, Babbe H, Misgeld T, Wekerle H, Laplaud DA, Hohlfeld R, Dornmair K.

Neurol Neuroimmunol Neuroinflamm. 2015 May 7;2(4):e107. doi: 10.1212/NXI.0000000000000107. eCollection 2015 Aug.

35.

Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study.

Lairy G, Zephir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, De Seze J.

Rev Neurol (Paris). 2015 May;171(5):407-14. doi: 10.1016/j.neurol.2015.03.006. Epub 2015 Apr 23.

PMID:
25912471
36.

Multiple sclerosis: From new concepts to updates on management.

Laplaud DA.

Presse Med. 2015 Apr;44(4 Pt 2):e101-2. doi: 10.1016/j.lpm.2015.03.003. Epub 2015 Mar 29. No abstract available.

PMID:
25823830
37.

The autoimmune concept of multiple sclerosis.

Nicol B, Salou M, Laplaud DA, Wekerle H.

Presse Med. 2015 Apr;44(4 Pt 2):e103-12. doi: 10.1016/j.lpm.2015.02.009. Epub 2015 Mar 23.

PMID:
25813101
38.

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.

Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, Brassat D, Loussouarn D, Salou M, Laplaud D, Casez O, Bockaert J, Marin P, Thouvenot E.

Mult Scler. 2015 Sep;21(10):1251-61. doi: 10.1177/1352458514561906. Epub 2015 Feb 19.

PMID:
25698171
39.

Tolerant Kidney Transplant Patients Produce B Cells with Regulatory Properties.

Chesneau M, Michel L, Dugast E, Chenouard A, Baron D, Pallier A, Durand J, Braza F, Guerif P, Laplaud DA, Soulillou JP, Giral M, Degauque N, Chiffoleau E, Brouard S.

J Am Soc Nephrol. 2015 Oct;26(10):2588-98. doi: 10.1681/ASN.2014040404. Epub 2015 Feb 2.

40.

Central Role of CD45RA- Foxp3hi Memory Regulatory T Cells in Clinical Kidney Transplantation Tolerance.

Braza F, Dugast E, Panov I, Paul C, Vogt K, Pallier A, Chesneau M, Baron D, Guerif P, Lei H, Laplaud DA, Volk HD, Degauque N, Giral M, Soulillou JP, Sawitzki B, Brouard S.

J Am Soc Nephrol. 2015 Aug;26(8):1795-805. doi: 10.1681/ASN.2014050480. Epub 2015 Jan 2.

41.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
42.

CPAP treatment supported by telemedicine does not improve blood pressure in high cardiovascular risk OSA patients: a randomized, controlled trial.

Mendelson M, Vivodtzev I, Tamisier R, Laplaud D, Dias-Domingos S, Baguet JP, Moreau L, Koltes C, Chavez L, De Lamberterie G, Herengt F, Levy P, Flore P, Pépin JL.

Sleep. 2014 Nov 1;37(11):1863-70. doi: 10.5665/sleep.4186.

43.

Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis.

Michel L, Chesneau M, Manceau P, Genty A, Garcia A, Salou M, Elong Ngono A, Pallier A, Jacq-Foucher M, Lefrère F, Wiertlewski S, Soulillou JP, Degauque N, Laplaud DA, Brouard S.

Clin Immunol. 2014 Dec;155(2):198-208. doi: 10.1016/j.clim.2014.09.011. Epub 2014 Sep 28.

PMID:
25267439
44.

Multiple sclerosis and pregnancy.

Bodiguel E, Bensa C, Brassat D, Laplaud D, Le Page E, Ouallet JC, Zephir H, De Seze J; Groupe de Réflexion sur la Sclérose en Plaques.

Rev Neurol (Paris). 2014 Apr;170(4):247-65. doi: 10.1016/j.neurol.2013.09.010. Epub 2014 Mar 28.

PMID:
24684929
45.

Characterization of antigen-specific B cells using nominal antigen-coated flow-beads.

Degauque N, Elong Ngono A, Akl A, Lepetit M, Crochette R, Giral M, Lepourry J, Pallier A, Castagnet S, Dugast E, Guillot-Gueguen C, Jacq-Foucher M, Saulquin X, Cesbron A, Laplaud D, Nicot A, Brouard S, Soulillou JP.

PLoS One. 2013 Dec 30;8(12):e84273. doi: 10.1371/journal.pone.0084273. eCollection 2013. Erratum in: PLoS One. 2014;9(7):e102845. Ngono, Annie Elong [corrected to Elong Ngono, Annie].

46.

Unique B cell differentiation profile in tolerant kidney transplant patients.

Chesneau M, Pallier A, Braza F, Lacombe G, Le Gallou S, Baron D, Giral M, Danger R, Guerif P, Aubert-Wastiaux H, Néel A, Michel L, Laplaud DA, Degauque N, Soulillou JP, Tarte K, Brouard S.

Am J Transplant. 2014 Jan;14(1):144-55. doi: 10.1111/ajt.12508. Epub 2013 Nov 13.

47.

Low physical activity is a determinant for elevated blood pressure in high cardiovascular risk obstructive sleep apnea.

Mendelson M, Tamisier R, Laplaud D, Dias-Domingos S, Baguet JP, Moreau L, Koltes C, Chavez L, de Lamberterie G, Herengt F, Levy P, Flore P, Pépin JL.

Respir Care. 2014 Aug;59(8):1218-27.

48.

[Nosology and etiologies of acute longitudinally extensive transverse myelitis].

Collongues N, Papeix C, Zéphir H, Audoin B, Cotton F, Durand-Dubief F, Vukusic S, Brassat D, Laplaud D, Marignier R; Groupe Nomadmus.

Rev Neurol (Paris). 2014 Jan;170(1):6-12. doi: 10.1016/j.neurol.2013.04.008. Epub 2013 Nov 21. French.

PMID:
24269116
49.

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP.

Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12.

PMID:
23895407
50.

Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.

Michel L, Vukusic S, De Seze J, Ducray F, Ongagna JC, Lefrère F, Jacq-Foucher M, Confavreux C, Wiertlewski S, Laplaud DA.

J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):279-83. doi: 10.1136/jnnp-2013-305298. Epub 2013 May 23.

PMID:
23704316

Supplemental Content

Loading ...
Support Center